Compare Adobe Systems Inc (ADBE) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Adaptive Biotechnologies Corp — how do they compare? Adobe Systems Inc trades at $260.55 (market cap $108.50B), while Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B). The key difference: Adobe Systems Inc is far larger — about 26.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | ADPT | |
|---|---|---|
Market Cap | $108.50B | $4.05B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $25.45 |
52-Week Low | $193.41 | $12.30 |
Enterprise Value | $109.94B | $4.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum above key support at $270. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability with 89.4% gross margins. Recent earnings beats and accelerating revenue growth contrast with mixed sentiment amid AI competition concerns and CEO transition uncertainty.
ADBE presents a compelling value proposition trading below analyst consensus targets with strong cash flow generation, though faces headwinds from AI disruption fears and sector volatility. The stock's current valuation at 15.62 P/E offers potential upside if execution continues, but requires monitoring of competitive threats and leadership stability.
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
